Covidien Quits Renal Denervation Race; Others Stick It Out, For Now
This article was originally published in The Gray Sheet
A Covidien executive said in an interview that the firm’s decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.
You may also be interested in...
Full Medtronic Results Offer Little Reason For Optimism On Renal Denervation
Renal denervation did not have a significant effect on systolic blood pressure in the SYMPLICITY HTN-3 trial, the first major sham-controlled trial of renal denervation for drug-resistant hypertension. The trial’s sponsor, Medtronic, had previously announced that it missed its primary endpoint but full results of the study were presented for the first time at the ACC meeting in Washington, DC on March 29.
Future Of Renal Denervation On Trial At ACC 2014 This Weekend
The full results of Medtronic’s SYMPLICITY HTN-3 trial, to be presented at the American College of Cardiology Scientific Sessions on March 29, could determine the fate of the renal denervation devices under development by several major companies for drug-resistant hypertension.
News Briefs: FDA Approves AF Catheter; Tax Reform Proposal; Renal Denervation
FDA approved a PMA supplement for Biosense Webster’s Thermocool SmartTouch, the first FDA-approved ablation catheter that can measure contact force in real time. J&J earns a CE mark for its Renlane renal denervation system. More news briefs.